216 related articles for article (PubMed ID: 12503030)
1. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
6. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
7. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
8. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
Cornelissen B; McLarty K; Kersemans V; Reilly RM
Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
11. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M
J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
Chakraborty AK; Liang K; DiGiovanna MP
Cancer Res; 2008 Mar; 68(5):1538-45. PubMed ID: 18316619
[TBL] [Abstract][Full Text] [Related]
16. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
18. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
19. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.
Sanabria-Figueroa E; Donnelly SM; Foy KC; Buss MC; Castellino RC; Paplomata E; Taliaferro-Smith L; Kaumaya PT; Nahta R
Mol Pharmacol; 2015 Feb; 87(2):150-61. PubMed ID: 25391374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]